June 3, 2020 IRDiRC welcomes Illumina Inc. as new member to its Company Constituent Committee, which brings together representatives from the for-profit pharmaceutical and biotech members of IRDiRC. Illumina is […]
Read MoreJune 2, 2020 The U.S. Food and Drug Administration (FDA) announced a Request for Information and Comment on Rare Disease Clinical Trial Networks. In particular, the FDA is requesting public input […]
Read MoreJune 2, 2020 The U.S. Food and Drug Administration (FDA) announced a Request for Information and Comment on Rare Disease Clinical Trial Networks. In particular, the FDA is requesting public input […]
Read MoreIRDiRC has been actively involved in the ECRD online conference that will take place this week: May 14 – 15, 2020.In particular, IRDiRC members joined several events planned during this […]
Read MoreIRDiRC is delighted to announce the new leadership on the Funders Constituent Committee (FCC), Dr Adam Hartman, NIH, as Chair and Dr Catherine Nguyen, INSERM, as Vice-Chair. Dr Hartman and […]
Read MoreA new IRDiRC publication is out! The Boosting delivery of rare disease therapies: the IRDiRC Orphan Drug Development Guidebook has been just published by Nature Reviews – Drug Discovery. The […]
Read MoreChrysalis Project The Funders Constituent Committee (FCC) has set up a jointly Task Force with the Companies Constituent Committee (CCC) and the Patient Advocates Constituent Committee (PACC). The overarching goal […]
Read MoreConsideration of legislative framework to support the diagnostic odyssey commonly encountered in the instance of rare disease. New paper on the undiagnostic odyssey, an important topic faced by many rare […]
Read MoreWORLD ORPHAN DRUG CONGRESS USA WEBINARS organizes this event scheduled on Wednesday April 22, 12 – 1pm EDT. There are many unprecedented challenges facing the rare disease community due to COVID-19 […]
Read MoreThe Rare Diseases Are Not Rare! Challenge is a competition sponsored by the National Center for Advancing Translational Sciences (NCATS), which is part of the National Institutes of Health. We are asking […]
Read More